NAMSA Acquires American Preclinical Services (APS)
March 2, 2021
Toledo-based NAMSA, a medical-device-focused contract research organization owned by ARCHIMED's MED Platform I, has acquired Minneapolis-based American Preclinical Services (APS). The add-on expands NAMSA's lab, surgical instrumentation and imaging capabilities and increases its footprint in Minnesota; debt financing for the deal was provided by funds managed by Ares Management Corporation.
- Buyers
- NAMSA, ARCHIMED (MED Platform I), Ares Management Corporation
- Targets
- American Preclinical Services (APS)
- Platforms
- NAMSA
- Industry
- Medical Devices
- Location
- Minnesota, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
NAMSA (ARCHIMED) Acquires Clinlogix
August 2, 2021
Healthcare Services
Toledo-based NAMSA, a portfolio company of healthcare-focused private equity firm ARCHIMED, has acquired Clinlogix, a Lower Gwynedd, Pennsylvania-based contract research organization (CRO) focused on medical device clinical trials. The deal expands NAMSA's clinical trial capacity by roughly 25%, deepens therapeutic expertise in neurology, oncology, urology and nephrology, and strengthens global trial capabilities with Clinlogix facilities in Japan, Germany and Colombia.
-
ArchiMed Acquires Majority Stake in NAMSA
September 1, 2020
Healthcare Services
ArchiMed, a healthcare-focused private equity firm, acquired a majority interest in NAMSA from the founding Gorski Family in an undisclosed equity recapitalization. NAMSA's president and senior management retained a significant double-digit stake; ArchiMed said the investment will support NAMSA's international growth and buy‑and‑build strategy to broaden services and accelerate expansion.
-
NAMSA Acquires WuXi AppTec U.S. Medical Device Testing Operations
January 17, 2025
Healthcare Services
NAMSA, an ARCHIMED-backed MedTech testing and clinical consulting firm, has acquired WuXi AppTec’s U.S. medical device testing operations (facilities in Minnesota and Georgia). The add-on expands NAMSA’s laboratory capacity and scientific capabilities across biocompatibility, microbiology, preclinical and extractables & leachables testing to better serve medical device manufacturers.
-
NAMSA Acquires Syntactx
January 5, 2021
Healthcare Services
NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.
-
NAMSA Acquires Perfectus Biomed Group
October 4, 2022
Medical Devices
NAMSA, a global MedTech CRO headquartered in Toledo, Ohio, has acquired Perfectus Biomed Group, a UK-based microbiological testing laboratory headquartered in Cheshire. The acquisition expands NAMSA's European laboratory services and deepens its microbiological testing and biofilm expertise to better support medical device clients; terms were not disclosed.
-
NAMSA Acquires SUAZIO
March 27, 2023
Healthcare Services
ARCHIMED-funded NAMSA has acquired SUAZIO, a Belgium-headquartered, data-driven life sciences and MedTech marketing and research consultancy. The add-on expands NAMSA's strategic consulting, market research and commercialization capabilities across medical devices and IVD markets; SUAZIO's founder reinvested proceeds and will continue to lead its consultancy services.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.